Table of Contents

Research Articles

• Research Articles

  CD25 Identifies a Subset of CD4⁺FoxP3⁻ TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer

  Ronald J. deLeeuw, David R. Kroeger, Sara E. Kost, Pheh-Ping Chang, John R. Webb and Brad H. Nelson

  Cancer Immunol Res March 1 2015 3 (3) 245-253; DOI:10.1158/2326-6066.CIR-14-0146

  
  

  deLeeuw and colleagues analyzed tumor-infiltrating lymphocytes (TIL) in primary high-grade serous ovarian cancer and discovered a novel subset of CD4⁺ TIL that are strongly associated with patient survival and hence warrant consideration as effector cells for immunotherapy.

• Research Articles

  Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

  Jeremy Bastid, Anne Regairaz, Nathalie Bonnefoy, Cécile Déjou, Jérôme Giustiniani, Caroline Laheurte, Stéphanie Cochaud, Emilie Laprevotte, Elisa Funck-Brentano, Patrice Hemon, Laurent Gros, Nicole Bec, Christian Larroque, Gilles Alberici, Armand Bensussan and Jean-François Eliaou

  Cancer Immunol Res March 1 2015 3 (3) 254-265; DOI:10.1158/2326-6066.CIR-14-0018

  
  

  Bastid and colleagues show that CD39 is highly expressed on tumor-infiltrating lymphocytes, tumor stroma, but also on tumor cells; treatment with CD39 inhibitors or blocking antibody alleviated the tumor-induced inhibition of T-cell proliferation and increased CTL- and NK cell–mediated cytotoxicity.

• Research Articles

  Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody

  Hong Xu, Ming Cheng, Hongfen Guo, Yuedan Chen, Morgan Huse and Nai-Kong V. Cheung

  Cancer Immunol Res March 1 2015 3 (3) 266-277; DOI:10.1158/2326-6066.CIR-14-0230-T

  
  

  Xu and colleagues describe a novel, fully humanized, aglycosylated bispecific antibody targeting GD2 pentasaccharide with femtomolar cytotoxic EC₅₀ against cancer cell lines that activates T cells in situ, drives intravenous T cells and monocytes to infiltrate tumor stroma, and ablates neuroblastoma and melanoma xenografts.

• Research Articles

  Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

  Rachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, Crystal M. Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, John P. Vasilakos, Linda Rolnitzsky, Judith D. Goldberg, John Mandeli, Sylvia Adams, Achim Jungbluth, Linda Pan, Ralph Venhaus, Patrick A. Ott and Nina Bhardwaj

  Cancer Immunol Res March 1 2015 3 (3) 278-287; DOI:10.1158/2326-6066.CIR-14-0202

  
  

  Sabado, Pavlick, and colleagues show that NY-ESO-1 protein in Montanide with or without topical resiquimod is safe, well-tolerated, and induces antibody and CD4 T-cell responses in most patients, but the addition of topical resiquimod is not sufficient to induce consistent NY-ESO-1–specific CD8 T-cell responses.

• Research Articles

  Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

  Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, Marta Colgan, Sarah DeNoble, Charles R. Terry, Elizabeth G. Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal and Jeffrey A. Sosman

  Cancer Immunol Res March 1 2015 3 (3) 288-295; DOI:10.1158/2326-6066.CIR-14-0207

  
  

  Johnson, Lovly, and colleagues performed a retrospective analysis of clinical outcomes following immunotherapy on 229 patients with melanoma with or without NRAS mutations and report that NRAS mutations in advanced melanoma correlate with increased benefit from immune-based therapies compared with other genetic subtypes.

• Research Articles

  Requirement for Innate Immunity and CD90⁺ NK1.1⁻ Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

  Marina Moskalenko, Michael Pan, Yichun Fu, Ellen H. de Moll, Daigo Hashimoto, Arthur Mortha, Marylene Leboeuf, Padmini Jayaraman, Sebastian Bernardo, Andrew G. Sikora, Jedd Wolchok, Nina Bhardwaj, Miriam Merad and Yvonne Saenger

  Cancer Immunol Res March 1 2015 3 (3) 296-304; DOI:10.1158/2326-6066.CIR-14-0120

  
  

  Moskalenko, Pan, and colleagues show in a B16 melanoma model that tumor clearance from the combined regimen of cytotoxic doses of cyclophosphamide and an antibody targeting melanoma differentiation antigen tyrosine-related protein 1 requires Fcγ receptors and innate CD90⁺NK1.1⁻ lymphocytes, not classical NK cells.